China Resources Double-Crane Pharmaceutical Co.,Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
8/10
|
14.39 | 41.44 | -65.27% | 14.14 | +1.74% |
| P/S |
|
1.88 | 20.2 | -90.71% |
|
|
| P/BV |
|
1.63 | 3.68 | -55.75% |
|
|
| P/FCF |
|
17.12 | 82.02 | -79.13% |
|
|
| Ev/Ebitda |
|
10.21 | 16.62 | -38.58% |
|
|
| Ev/S |
|
1.47 | 25.64 | -94.29% |
|
|
| Ev/FCF |
|
14.6 | 85.08 | -82.84% |
|
|
| E/P |
|
0.0759 | 0.0217 | 250.11% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
7/10
|
20.81 | 6.32 | 229.16% | 17.92 | +16.15% |
| ROE |
|
12.63 | 6.65 | 89.82% |
|
|
| ROA |
|
8.91 | 3.59 | 148.53% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
13.04 | -76.75 | -116.99% |
|
|
| ROCE |
|
0 | 19.43 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.1339 | 0.7406 | -81.91% | 0.1083 | +23.65% |
| Nеt Debt/Ebitda |
|
0 | -0.1122 | -100% |
|
|
| Debt/Ratio |
|
0.0171 | 0.1008 | -83.08% |
|
|
| Debt/Equity |
|
0.0368 | 0.212 | -82.65% |
|
|
| Debt/Net Income |
|
0.1975 | 1.37 | -85.63% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.3991 | -100% | 3.15 | -100% |
| Number of years of dividend growth |
|
0 | 1 | -100% | ||
| DSI |
|
0.7143 | 0.6935 | 3% |
|
|
| Average dividend growth |
|
10.87 | 3.04 | 257.47% |
|
|
| Average percentage for 5 years |
|
3.15 | 1.4 | 125.21% |
|
|
| Average percentage for payments |
|
76.21 | 45.07 | 69.09% |
|
|
| Difference from average difference in sector |
|
-0.3991 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
2/10
|
8.97 | 23.95 | -62.55% | ||
| Growth impulse Ebitda in 5 years |
|
-9.74 | 12.85 | -175.8% | ||
| Growth impulse Net Income in 5 years |
|
26.34 | 62.77 | -58.04% | ||
| Growth impulse FCF in 5 years |
|
-14.34 | 30.35 | -147.25% | ||
| Growth impulse EPS in 5 years |
|
29.5 | 82.9 | -64.41% |
IP Score
5.62/10
